Although reduced perfusion is observed in ATG12-deficient tumors and thus a larger hypoxic fraction would be expected, immunohistochemistry of the exogenous hypoxia marker pimonidazole displayed no changes in the relative fraction of the viable tumor area (Figure 4F). The gene discussed is ATG12; the disease is neoplasm.